A compound for use in the treatment of cell proliferative diseases, wherein the compound is a compound having the following general formula A or a pharmaceutically acceptable salt thereof: wherein: is an aryl, heteroaryl, alicyclic, or heteroalicyclic ring, which may be unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of: a halogen atom, CN, R 3, OR 3, SR 3, N(R 3) 2, C R 3, C OR 3, NR 3 C R 3, C NR 3, SO 2 R 3, NR 3 SO 2 R 3, and SO 2 N(R 3) 2; X is -O, -NR 4, -NSO 2 R 4, -CH 2, -CHR 4, or -C(R 4) 2; H a and H b are each hydrogen atoms; R 1 and R 2 are: each independently selected from the group consisting of: a hydrogen, halogen atom, CN, R 3, OR 3, SR 3, N(R 3) 2, C R 3, C OR 3, NR 3 C R 3, C NR 3, SO 2 R 3, NR 3 SO 2 R 3, and SO 2 N(R 3) 2; or connected to form a 5 or 6 membered ring which is fused to ring D, wherein the 5 or 6 membered ring is either unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of: a halogen atom, CN, R 3, OR 3, SR 3, N(R 3) 2, C R 3, C OR 3, NR 3 C R 3, C NR 3, SO 2 R 3, NR 3 SO 2 R 3, and SO 2 N(R 3) 2; R 3 is independently hydrogen or a substituted group selected from the group consisting of: a C 1-6 aliphatic group; a monocyclic 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or a bicyclic 8-10 membered saturated, partially unsaturated, or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and R 4 is hydrogen or an unsubstituted or a substituted alkyl, aryl or heteroaryl group. X is -O, -NR 4, -NSO 2 R 4, -CH 2, -CHR 4, or -C(R 4) 2; H a and H b are each hydrogen atoms; R 1 and R 2 are: each independently selected from the group consisting of: a hydrogen, halogen atom, CN, R 3, OR 3, SR 3, N(R 3) 2, C R 3, C OR 3, NR 3 C R 3, C NR 3, SO 2 R 3, NR 3 SO 2 R 3, and SO 2 N(R 3) 2; or connected to form a 5 or 6 membered ring which is fused to ring D, wherein the 5 or 6 membered ring is either unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of: a halogen atom, CN, R 3, OR 3, SR 3, N(R 3) 2, C R 3, C OR 3, NR 3 C R 3, C NR 3, SO 2 R 3, NR 3 SO 2 R 3, and SO 2 N(R 3) 2; each independently selected from the group consisting of: a hydrogen, halogen atom, CN, R 3, OR 3, SR 3, N(R 3) 2, C R 3, C OR 3, NR 3 C R 3, C NR 3, SO 2 R 3, NR 3 SO 2 R 3, and SO 2 N(R 3) 2; or connected to form a 5 or 6 membered ring which is fused to ring D, wherein the 5 or 6 membered ring is either unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of: a halogen atom, CN, R 3, OR 3, SR 3, N(R 3) 2, C R 3, C OR 3, NR 3 C R 3, C NR 3, SO 2 R 3, NR 3 SO 2 R 3, and SO 2 N(R 3) 2; R 3 is independently hydrogen or a substituted group selected from the group consisting of: a C 1-6 aliphatic group; a monocyclic 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or a bicyclic 8-10 membered saturated, partially unsaturated, or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and R 4 is hydrogen or an unsubstituted or a substituted alkyl, aryl or heteroaryl group.